Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs ProShares Ultra Gold ETF — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.65 (market cap $977.37M), while ProShares Ultra Gold ETF trades at $45.58 (market cap $730.54M). The key difference: Maravai LifeSciences Holdings Inc. Class A Common Stock is the larger of the two by market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, ProShares Ultra Gold ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and ProShares Ultra Gold ETF for 25 Days on average.
| MRVI | UGL | |
|---|---|---|
Market Cap | $977.37M | $730.54M |
Volume | 2,742,564 | 4,212,910 |
Sector | Health | Leveraged / Inverse |
52-Week High | $9.00 | $85.62 |
52-Week Low | $2.83 | $42.79 |
Typical Hold Time | 0 Days | 25 Days |
Enterprise Value | $1.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
UGL stock trades at $45.70, down 0.39% with bearish technical signals from moving averages. The stock faces pressure from broader market headwinds including rising Treasury yields and Federal Reserve policy uncertainty. Recent news highlights gold's struggle to maintain momentum despite intermittent safe-haven demand, with prices testing key support levels amid mixed economic data.
The outlook remains cautious with technical indicators suggesting continued near-term pressure. Investment opportunity exists for contrarian investors if gold regains its safe-haven appeal, though risks include persistent rate hike expectations and dollar strength. The stock's performance remains tightly linked to gold price movements and macroeconomic developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
